DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

“…HCC incidences in males at younger age groups (age <50 years old), particularly in those with age <34 groups, showed an accelerating decrease over time, whereas HCC incidences significantly declined in the female population across all age groups except for those under 19 years of age. …”

No discernible effect of high-dose 5-HT_2AR blockade on error rates in the reward-size task. by Yukiko Hori (299784)

Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

“…In a reduced model with seven fields, culture and leisure no longer had a significant effect while ceremonies decreased transmission by 5% (0.95; 0, 0.96). …”

Tl damages rat kidney. by Sho Sugahara (11895828)

Subjects:

Increased biogenesis of ribosomes in the kidneys from rats administered Tl. by Sho Sugahara (11895828)

Subjects:

S1 File - by Sho Sugahara (11895828)

Subjects:

Electron microscopic analysis of kidneys from rats administered Tl. by Sho Sugahara (11895828)

Subjects:

Cell viability of U-87 MG cell cultures treated with Ser/5-HT or fluoxetine. by Glaucia Vilar-Pereira (686134)

LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

Fig 5 - by Harshita Sharma (4836180)

The basic characteristics of the included studies. by Junyin Pan (20700411)

Subjects:

Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Subjects:

Assessment of study bias in the included research. by Junyin Pan (20700411)

Subjects:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

“…<i>daf-16</i> mutants are documented to have lowered locomotory ability vs. WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”